Last $57.53 USD
Change Today +1.37 / 2.44%
Volume 110.1K
ALKS On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 10:50 AM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

alkermes plc (ALKS) Snapshot

Open
$56.21
Previous Close
$56.16
Day High
$57.54
Day Low
$56.17
52 Week High
12/8/14 - $59.69
52 Week Low
10/13/14 - $38.49
Market Cap
8.4B
Average Volume 10 Days
753.1K
EPS TTM
$-0.42
Shares Outstanding
146.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ALKERMES PLC (ALKS)

alkermes plc (ALKS) Related Businessweek News

View More BusinessWeek News

alkermes plc (ALKS) Details

Alkermes Public Limited Company, an integrated biopharmaceutical company, develops medicines that enhance patient outcomes. The company offers RISPERDAL CONSTA for schizophrenia and bipolar I disorder; INVEGA SUSTENNA to treat schizophrenia; AMPYRA/FAMPYRA to treat multiple sclerosis; BYDUREON to treat type II diabetes; VIVITROL for alcohol and opioid dependence; TRICOR, LIPANTHYL, LIPIDIL, and SUPRALIP to lower cholesterol; ZANAFLEX for muscle spasticity; AVINZA for moderate to severe pain; EMEND to treat nausea associated with chemotherapy and surgery; and FOCALIN XR and RITALIN LA for attention deficit and hyperactivity disorder. Its products also include MEGACE ES to treat cachexia associated with AIDS; LUVOX CR for obsessive-compulsive disorder; RAPAMUNE to prevent renal transplant rejection; NAPRELAN for mild to moderate pain indications; VERAPAMIL SR, VERELAN, VERELAN PM, VERAPAMIL PM, VERECAPS, UNIVER, and AFEDlTAB CR for hypertension; DILZEM SR, DILZEM XL, DILTELAN, and CARDIZEM CD for hypertension and/or angina; and ZOHYDRO ER for severe pain. In addition, it is developing Aripiprazole Lauroxil for the treatment of schizophrenia; ALKS 33, which has completed Phase II study for modulation of brain opioid receptors; ALKS 5461 that is under Phase III study for the treatment of depressive disorder; ALKS 3831, a phase II study medicine to treat schizophrenia; ALKS 8700, a prodrug of monomethyl fumarate to treat multiple sclerosis; ALKS 7106, a small-molecule product candidate to treat pain with intrinsically low potential for abuse and overdose death; and RDB 1419, a proprietary biologic cancer immunotherapy candidate. The company serves pharmaceutical wholesalers, specialty pharmacies, and specialty distributors directly through its sales force. It has collaboration agreements with Janssen Pharmaceutica, NV; AstraZeneca plc; Acorda Therapeutics, Inc.; and other collaboration partners. The company was founded in 1987 and is headquartered in Dublin, Ireland.

1,250 Employees
Last Reported Date: 02/27/14
Founded in 1987

alkermes plc (ALKS) Top Compensated Officers

Chairman of the Board and Chief Executive Off...
Total Annual Compensation: $810.2K
President
Total Annual Compensation: $579.9K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $444.1K
Chief Operating Officer, Chief Risk Officer a...
Total Annual Compensation: $437.5K
Chief Legal Officer, Chief Compliance Officer...
Total Annual Compensation: $435.5K
Compensation as of Fiscal Year 2013.

alkermes plc (ALKS) Key Developments

Alkermes plc Announces Initiation of Clinical Study of Extended Durations of Aripiprazole Lauroxil for Treatment of Schizophrenia

Alkermes plc announced the initiation of a phase 1 clinical study of extended dosing intervals of aripiprazole lauroxil, the company’s investigational, novel, long-acting injectable atypical antipsychotic for the treatment of schizophrenia. The randomized, open-label study of approximately 140 patients with schizophrenia will evaluate the pharmacokinetics, safety and tolerability of aripiprazole lauroxil administered over two new extended durations – once every six weeks, and once every two months. A New Drug Application (NDA) for aripiprazole lauroxil one-month is currently under review with the U.S. Food and Drug Administration (FDA) and has been assigned a Prescription Drug User Fee Act (PDUFA) date of Aug. 22, 2015. The phase 1, randomized, open-label study will evaluate the pharmacokinetics, safety and tolerability of aripiprazole lauroxil when administered at one-month, six-week and two-month intervals. Following a 30-day screening period, approximately 140 patients with stable schizophrenia will be randomized to receive one of four different dosing regimens of aripiprazole lauroxil (441 mg once per month, 882 mg every six weeks, or one of two formulations of 1,064 mg every two months) for a total of six treatment months. Results from this phase 1 study are expected mid 2016.

Alkermes plc Presents at NASDAQ OMX 31st Investor Program, Dec-02-2014 10:45 AM

Alkermes plc Presents at NASDAQ OMX 31st Investor Program, Dec-02-2014 10:45 AM. Venue: The Waldorf Hilton, Aldwych, London, WC2B 4DD, United Kingdom.

Alkermes plc Announces Unaudited Consolidated Financial Results for the Second Quarter and Six Months Ended September 30, 2013; Revises Earnings Guidance for the Full Year of 2014

Alkermes plc announced unaudited consolidated financial results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenues of $159.992 million against $139.802 million a year ago. Total revenues were driven primarily by growth from its portfolio of five key commercial products which grew 38% compared to last year and now represent approximately 73% of its total revenue compared to approximately 59% in the same period last year. Operating loss was $32.738 million against $3.878 million a year ago. Loss before income taxes was $36.433 million against $7.529 million a year ago. Net loss – GAAP was $39.956 million or $0.27 per diluted share against $7.762 million or $0.06 per diluted share a year ago. Non-GAAP earnings per share – diluted were $0.03 against $0.22 a year ago. Non-GAAP net income was $3.899 million against $31.765 million a year ago. Capital expenditure was $8.888 million against $5.573 million a year ago. Negative free cash flow was $4.989 million against positive free cash flow of $26.192 million a year ago. For the nine months, the company reported total revenues of $443.628 million against $441.855 million a year ago. Operating loss was $71.456 million against operating income of $28.633 million a year ago. Loss before income taxes was $54.809 million against income before income taxes of $10.387 million a year ago. Net loss – GAAP was $60.575 million or $0.42 per basic and diluted share against net income of $2.569 million or $0.02 per basic and diluted share a year ago. Non-GAAP earnings per share – diluted were $0.25 against $0.92 a year ago. Non-GAAP net income was $37.772 million against $130.871 million a year ago. Capital expenditure was $20.326 million against $17.457 million a year ago. Free cash flow was $17.446 million against $113.414 million a year ago. The company revises earnings guidance for the full year of 2014. For the period, the company expects net other income to range from $85 million to $90 million, up from the previous range of $25 million to $30 million, reflecting approximately $60 million that Alkermes will earn related to the Civitas transaction. The company now expects GAAP net loss to range from $50 million to $70 million, or a basic and diluted loss per share of approximately $0.34 to $0.48, based on weighted average basic and diluted share counts of approximately 145 million shares outstanding. This compares to previous expectations of a GAAP net loss in the range of $90 million to $110 million, or a basic and diluted loss per share of $0.62 to $0.76, based on weighted average basic and diluted share counts of approximately 145 million shares outstanding. The company continues to expect non-GAAP net income to range from $30 million to $50 million, and non-GAAP diluted EPS to range from $0.19 to $0.32, based on a weighted average diluted share count of approximately 155 million shares outstanding. The company continues to expect capital expenditures to be approximately $30 million. The company continues to expect free cash flow of up to $20 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALKS:US $57.53 USD +1.37

ALKS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioMarin Pharmaceutical Inc $90.45 USD +2.27
Jazz Pharmaceuticals PLC $166.28 USD +0.95
Lupin Ltd 1,407 INR +5.85
Pacira Pharmaceuticals Inc/DE $93.02 USD +0.93
Salix Pharmaceuticals Ltd $117.03 USD +2.11
View Industry Companies
 

Industry Analysis

ALKS

Industry Average

Valuation ALKS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.2x
Price/Book 6.2x
Price/Cash Flow 440.6x
TEV/Sales 12.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALKERMES PLC, please visit www.alkermes.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.